Google Search

Search

Already a Member ?

Investment Opportunities & Business Ideas in Morocco, Africa - Identification and Selection of right Project, Thrust areas for Investment, Industry Startup and Entrepreneurship Projects

We can provide you detailed project reports on the following topics. Please select the projects of your interests.

Each detailed project reports cover all the aspects of business, from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. The scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet etc.

We also offer self-contained Pre-Investment and Pre-Feasibility Studies, Market Surveys and Studies, Preparation of Techno-Economic Feasibility Reports, Identification and Selection of Plant and Machinery, Manufacturing Process and or Equipment required, General Guidance, Technical and Commercial Counseling for setting up new industrial projects on the following topics.

Many of the engineers, project consultant & industrial consultancy firms in India and worldwide use our project reports as one of the input in doing their analysis.

We can modify the project capacity and project cost as per your requirement.
We can also prepare project report on any subject as per your requirement.

Page 10 of 31 | Total 306 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 30 31   Next »

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Select all | Clear all Sort by

Oxygen and Nitrogen Gas Production

Oxygen and Nitrogen Gas Production. Industrial Gas Plant India industrial gases market forecast to grow at a CAGR of over 11% Oxygen Gas Oxygen and nitrogen are the most important industrial gases finding its application in large quantities in metal fabrication and cutting industries. It is used in electric arc steel furnaces for decarburization and scrap matting. Oxygen is also used in medical treatment and for breathing at high altitude flying. Some quantities of liquid oxygen are used in explosives, chemicals and petrochemicals industries as an oxidizing and catalytic agent. As the quantity of oxygen required in integrated steel plants is huge, the excess of oxygen is compressed and bottled in steel cylinders and supplied to engineering industries such as manufacture of machine tools, industrial machinery, automobiles and component manufacturers, fabricators of chemical plants, storage tanks, and furniture and building elements. Nitrogen Gas Nitrogen is a colorless, odorless, inert and non-flammable gas. Although it is inert in nature, it reacts with other compounds under specific conditions. Industrial Nitrogen has a varied range of application in different industries. Nitrogen gas is used in the production of ammonia which in turn is used for the manufacture of urea and ammonium phosphate, which are fertilizers of great use. Nitrogen gas is used for blanketing hazardous chemicals which is an inert atmosphere. Nitrogen gas is used for purging purposes. Nitrogen gas is used for the purification of other gases with extremely low boiling points, such as hydrogen scrubbing. High purity nitrogen is used in strip steel annealing prior to tin plating. Human blood and cattle sperm cells are pressured by using nitrogen liquid freezing method. Large quantities of liquid nitrogen are employed in the preservation of food by rapid freezing. Liquid nitrogen is also used to maintain low temperatures during the transportation of frozen food. The demand of oxygen and nitrogen gas will increase in future Uses: Oxygen gas • Oxygen is also used in many industrial, commercial, medical, and scientific applications. It is used in blast furnaces to make steel, and is an important component in the production of many synthetic chemicals, including ammonia, alcohols, and various plastics. • The steel industry also uses oxygen gas in an oxy-acetylene flame, for scale removal from billets, and in oxygen lances, for cutting out imperfect ions. • The continuous gasification of coal or other solid fuel, oxygen gas admixed with steam is passed into the fuel bed and maintains a sufficiently high temperature to allow the waleragas reaction to proceed smoothly. • Oxygen gas is used in hospitals (to enrich air in respirators and to mix with anesthetics), aviation (for pilots' air supply), and pollution control. The space program was a major user of oxygen, • In the chemical and petrochemical industries, as well as in the oil and gas sector oxygen is used in commercial volumes as an oxidizer in chemical reactions. The use of oxygen in gas-flame operations, such as metal welding, cutting and brazing is one of the most significant and common applications of this gas. Nitrogen Gas • Nitrogen is used primarily as a freezing agent and a blanketing agent. About 21% of nitrogen produced is used for freezing • Other freezing applications include cryogenic size reduction of plastics, rubber, spices, and pharmaceuticals. About 33% of all nitrogen produced is used for blanketing, mostly in chemical processing and the electronics industry (14% each), with some application in the primary metals industry (5%). • Demand for nitrogen has been growing steadily 1n the liquefied industrial gases market and the chemical industry. In the aluminum industry, nitrogen has been replacing inert gas generators. The enhanced -oil products industry also requires fairly large quantities of gaseous nitrogen. • Nitrogen requirements for steel manufacture are modest and seldom exceed a small fraction of the oxygen flow. Some nitrogen~lso is used as the principal refrigerant in air separation cycles and as clean-up gas (to remove unwanted carbon dioxide and water). • Chemical Plants – Nitrogen is used to displace oxygen and prevent explosions in highly dangerous atmospheres, such as chemical plants and manufacturing facilities. Tire Inflation – Nitrogen offers many benefits when used to fill tires, such as giving them a longer life by reducing oxidation • Food Packaging – Nitrogen is used to displace oxygen in food packaging. By eliminating the oxygen, the food can last longer. It can also add a cushion around the food to keep it safe from breaking in transport. • Light Bulb Production – In incandescent light bulbs, nitrogen gas is often used as a cheaper alternative to argon. • Chemical Plants – Nitrogen is used to displace oxygen and prevent explosions in highly dangerous atmospheres, such as chemical plants and manufacturing facilities. • Tire Inflation – Nitrogen offers many benefits when used to fill tires, such as giving them a longer life by reducing oxidation. It also improves tire pressure retention to give drivers better gas mileage. • Electronics – When electronics are being assembled, nitrogen gas is used for soldering. Using nitrogen reduces the surface tension to provide a cleaner breakaway from the solder site. • Stainless Steel Manufacturing – By electroplating the stainless steel with nitrogen, the finished product is stronger and resistant to corrosion. • Pollution Control – Nitrogen gas can be used to remove the VOCs in liquids before they are discarded. • Pharmaceuticals – Almost every major drug class contains some nitrogen, even antibiotics. Nitrogen, in the form of nitrous oxide, is also used as an anesthetic. • Mining – In the mining industry, nitrogen gas is used to quickly extinguish fires by eliminating the oxygen from the air. And when an area is going to be abandoned, they use nitrogen to ensure the area will not explode. • Mild steel & carbon steel annealing • Electronic industries like semiconductors etc. • Blanketing during chemical reactions • Auto industries for Sintering, Brazing & Soldering • Food packaging • Tire filling • Metal powder formation Market Outlook The medical gases market size in India, in volume terms, is forecast to witness a two folds increase by 2019, exhibiting a CAGR of about 15% during 2014-19. The medical gases market in India is highly dominated by region-specific players, which are offering a stiff competition to multinational companies. India’s specialization in cardiology, orthopedic surgery, etc., is expected to drive healthcare demand, particularly for medical oxygen and nitrous oxide, which are vital requirements of any healthcare setup. Currently, the northern region, followed by the southern region, is the leading demand generators for medical gases, particularly medical oxygen gas. Oxygen Demand : Past and Future Year (In Million m3) 1990-91 450 2000-01 1335 2001-02 1525 2002-03 1725 2003-04 1975 2004-05 2315 2005-06 2760 2006-07 3360 2007-08 3730 2008-09 4910 2009-10 5400 2010-11 6250 2011-12 7210 2012-13 8200 2013-14 9165 2014-15 10000 2015-16 11250 2016-17 12800 2017-18 13950 2018-19 15700 2019-20 17230 2024-25 27125 Global Oxygen Market: Overview Oxygen is a colorless gas which is a paramount factor to sustain life. Oxygen is available in cylinders, containers, and cans. They are mostly used for industrial, medical, and scientific applications. Oxygen is used as an oxidizing agent and as a catalyst in various scientific and industrial processes. The oxygen market is growing at a significant pace and the growth in the oxygen market has resulted in an increase in the related markets such as medical oxygen generators, air-oxygen blenders, and stationary and portable oxygen concentrators. The global oxygen market is divided into its form, application, end-users, and geography. On the basis of a form of oxygen, the market is segregated into solid, liquid, and gaseous. Based on application, the market is classified into cosmetics, pharmaceutical, automobiles, and mining and mineral processing applications. On the basis of end-users, the market is categorized into industrial, medical, and scientific sectors. Diversification of the market on the basis of the region is seen into Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. Global Oxygen Market: Regional Analysis The largest share in the oxygen market is held by the Asia Pacific region. This growth can be attributed to reasons such as the growth of manufacturing sector and healthcare. Also, growth in the mineral and mining processing, where oxygen is a key catalyst, helps in the expansion of oxygen market in the region. Regions such as China, Japan, India, Australia, and New Zealand are showing major contribution in the Asia Pacific market. Key Players ? Hale Hamilton ? Maximator GmbH ? Hydrotechnik UK Ltd ? HyDAC ? Hydraulics International ? Inc ? Accudyne Industries ? Semmco Limited among Industrial Nitrogen Gas Market The market is witnessing a rise in demand from the food and beverages market. Its freezing property has expanded its use in blood banks, cryogenic treatments and plastic and rubber industries. Demand from end-users such as metal manufacturers, chemical and transportation industries are also propelling the industry to grow. Application wise its use can be segmented into metal manufacturing, oil and gas sector, petrochemical, pharmaceutical and healthcare, chemical, food and beverage industry and electronics. Food packaging - to displace the Oxygen from packaging that helps the food product to last long, used as fertilizer when combined with Ammonia to form Nitrates, Tire Inflation - by improving life of the tire and getting better mileage. The demand for industrial gases also continued to remain strongly driven by an increase in investments in infrastructure development and petroleum reserves in emerging markets. In fact, metal fabrication and production sector are expected to remain the second major sector for industrial gases, next to petroleum refining. Over the longer term to 2022, the annual growth rate in the industrial gas market is expected to significantly exceed the rate of industrial production driven by multitude of factors including opening of new startups, rapid industrialization of emerging economies, increasing demand for energy, environment regulations, improving healthcare sector, and advancements in industrial technology. Tags #Oxygen_and_Nitrogen_Gas_Plant, #Production_of_Oxygen_Gas, How Oxygen is Made, Producing Oxygen Gas, Oxygen Plant, Nitrogen Plants, #Oxygen_Plant, Industrial Oxygen Plant, #Industrial_Gases, Making of Oxygen Gas, Oxygen Production, Manufacturing Process of Oxygen Gas Plant, Oxygen Plant Manufacturing Process, Oxygen Plant in India, Oxygen Gas Production Plant, Oxygen Gas Manufacturing Plant, Manufacturing of Oxygen Gas, Project Report on Oxygen Gas Plant, Oxygen Gas Manufacture in India, Manufacturing of Medical Gases, Oxygen Gas Manufacturing Unit, Nitrogen Gas Plant, Oxygen Gas Plant Project Cost, #Oxygen_&_Nitrogen_Gas_Plant, Oxygen and Nitrogen Gas Plant Manufacturing Plant, Industrial Gas Plants, Uses and Applications of Nitrogen Gas, Nitrogen Gas Production, Nitrogen Gas Manufacturing Process, #Production_of_Nitrogen, Manufacturing Process of Nitrogen Gas, Manufacturing Process of Oxygen Nitrogen Gas Plant, Setting up Oxygen and Nitrogen Gas Plant, #Industrial_&_Medical_Oxygen_and_Nitrogen_Gases, Industrial Oxygen Gas Filling Plant, Medical Gases, #Oxygen_Gas_Plant_Project Cost, Industrial Oxygen Plant Project Report Pdf, Medical Oxygen Plant Setup Cost in India, Oxygen Gas Business, #How_to_Start_Oxygen_Plant, Project Report on Oxygen & Nitrogen Gas Industry, Detailed Project Report on Oxygen & Nitrogen Gas Plant, #Project_Report_on_Oxygen_&_Nitrogen_Gas_Plant, Pre-Investment Feasibility Study on Oxygen & Nitrogen Gas Plant, Techno-Economic feasibility study on Oxygen & Nitrogen Gas Plant, Feasibility report on Oxygen & Nitrogen Gas Plant, Free Project Profile on Oxygen & Nitrogen Gas Plant, Project profile on Oxygen & Nitrogen Gas Plant, Download free project profile on Oxygen & Nitrogen Gas Plant
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Lithium Ion Battery (Battery Assembly)

Lithium-ion batteries are all about the movement of lithium ions: the ions move one way when the battery charges (when it's absorbing power); they move the opposite way when the battery discharges (when it's supplying power): Lithium batteries are now powering a wide range of electrical and electronical devices, including laptop computers, mobile phones, power tools, telecommunication systems and new generations of electric cars and vehicles. The high cost, associated with batteries that are used in the electric vehicles, is considered to be critical for India's ambitious target. To counter this, the Government of India is planning to set up lithium-ion battery manufacturing units in India, aggressively. The Indian automobile sector is one of the most prominent sectors of the country, accounting for nearly 7.1% of the national GDP. The industry produced a total of 25.31 million vehicles, including commercial, passenger, two, and three vehicles and commercial quadricycle in April-March 2017, as against 24.01 million in April-March 2016. However, India has set itself an ambitious target of having only electric vehicles (EV) by 2030, which is expected to increase the demand for lithium-ion batteries in India, significantly.
Plant capacity: 90 Volt, 180 AH Lithium Ion Battery Pack:100,000 Nos per AnnumPlant & machinery: 1017 Lakh
Working capital: -T.C.I: Cost of Project :4978 Lakh
Return: 34.00%Break even: 52.00%
Add to Inquiry Add to Inquiry Basket

Lithium Ion Battery (Battery Assembly)

Lithium batteries are now powering a wide range of electrical and electronical devices, including laptop computers, mobile phones, power tools, telecommunication systems and new generations of electric cars and vehicles. Lithium metal batteries and lithium ion batteries. Basically, the difference between them is that lithium metal batteries are those that are not rechargeable, thus, primary, and lithium ion batteries are those that can be recharged. As an example, your laptop or cell phone is likely to have a lithium ion battery, whereas your watch may have a lithium metal battery. During charging, lithium ions (yellow circles) flow from the positive electrode (red) to the negative electrode (blue) through the electrolyte (gray). Electrons also flow from the positive electrode to the negative electrode, but take the longer path around the outer circuit. The electrons and ions combine at the negative electrode and deposit lithium there. The India lithium-ion battery market is expected to grow at a robust CAGR of 29.26% during the forecast period, 2018-2023. The Indian automobile sector is one of the most prominent sectors of the country, accounting for nearly 7.1% of the national GDP. The industry produced a total of 25.31 million vehicles, including commercial, passenger, two, and three vehicles and commercial quadricycle in April-March 2017, as against 24.01 million in April-March 2016. The high cost of lithium-ion batteries was considered earlier as one of the principal difficulties for the implementation of India’s ambitious all-electric vehicle target by 2030. The Indian automobile sector is one of the most prominent sectors of the country, accounting for nearly 7.1% of the national GDP.
Plant capacity: 48 Volt, 20 AH Lithium-Ion Battery Pack: 3498 Nos Per DayPlant & machinery: 5053 Lakh
Working capital: -T.C.I: Cost of Project: 7215 Lakh
Return: 29.00%Break even: 45.00%
Add to Inquiry Add to Inquiry Basket

Solar Panel

Solar panel refers either to a photovoltaic module, a solar thermal energy panel, or to a set of solar photovoltaic (PV) modules electrically connected and mounted on a supporting structure. A PV module is a packaged, connected assembly of solar cells. Solar panels can be used as a component of a larger photovoltaic system to generate and supply electricity in commercial and residential applications. Each module is rated by its DC output power under standard test conditions (STC), and typically ranges from 100 to 320 watts. The efficiency of a module determines the area of a module given the same rated output - an 8% efficient 230 watt module will have twice the area of a 16% efficient 230 watt module. There are a few solar panels available that are exceeding 19% efficiency. A single solar module can produce only a limited amount of power most installations contain multiple modules. A photovoltaic system typically includes a panel or an array of solar modules, an inverter, and sometimes a battery and/or solar tracker and interconnection wiring. India solar power products market is projected to grow at a CAGR of more than 11% to surpass $ 7.6 billion by 2024 on the back of increasingly stringent policy and regulatory framework and rising environmental concerns. The Ministry of New and Renewable Energy has set a target of 100 GW of solar power generation capacity by 2022. To achieve the target, government has taken several initiatives in the form of offering subsidies, financial assistance, incentives to manufacturers, power producers and even customers. The government has also partnered with several nodal agencies at the central and state levels for the installation of off-grid SPV systems. Subsidies are made available to the customers to encourage installation of grid connected rooftop photovoltaics. Additionally, rising per capita income and developments in the photovoltaic technologies are further anticipated to positively influence India solar power products market during forecast period. Few Indian major players are as under Alectrona Energy Pvt. Ltd Alpex Solar Pvt. Ltd. Bright Solar Ltd. Central Electronics Ltd. Devsun Solar Pvt. Ltd
Plant capacity: Solar Panel:83.3 KW / dayPlant & machinery: 162 lakhs
Working capital: -T.C.I: Cost of Project : Rs 804 lakhs
Return: 28.00%Break even: 54.00%
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients (API) Amoxicillin Trihydrate, Azithromycin & Paracetamol

Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. Azithromycin is used to treat certain bacterial infections, such as bronchitis; pneumonia; sexually transmitted diseases (STD); and infections of the ears, lungs, sinuses, skin, throat, and reproductive organs. Paracetamol is a commonly used medicine that can help treat pain and reduce a high temperature (fever). It is often recommended as one of the first treatments for pain, as it's safe for most people to take and side effects are rare. India is the seventh largest country in the world and has the second highest population. It has a parliamentary democratic form of government and has abundant natural resources and sufficient oil reserves. Huge investment promises from different countries predict a bright future for India. It has a well-developed administration and an independent judicial system with an ever-growing consumer base. It has a huge pool of hard-working skilled workers in all fields. The government has set up tax and non-tax incentives to establish new industrial entities in specific sectors, which include energy, ports, highways, electronics, and software. The Make in India initiative was launched by the government in 2014 and received an excellent response from the developed nations. The government has also created special areas dedicated to export, called export-processing zones (EPZs) or special economic zones (SEZs), to encourage foreign investment. The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. Patent expirations of blockbuster drugs give rise to generic versions of these molecules, wherein the manufacturers bear the cost. After a patent expires, R&D investments done by the company are no longer beneficial for the company. API production requires a huge capital amount as the process needs extremely systematic protocols. Thus, pharmaceutical companies benefit from outsourcing API production, as it eliminates the need for labor force and installing expensive manufacturing units. Strategic outsourcing allows companies to focus on their core competencies, ultimately resulting in increased productivity. These factors are also projected to drive the active pharmaceutical ingredient market growth. The growth of active pharmaceutical ingredients market is marked by the huge demand for drugs like analgesics, anti-infectives and diabetes, and pain management drugs. But with the rising trend of increasing research and development (R&D) activities, the demand is experiencing a shift towards the advancement of complex APIs that find use in novel formulations, thereby targeting niche therapeutic areas. This facilitates the development of new technologies and ensures a high quality product. Among the problems for pharmaceutical supply chains during this pandemic are the restrictions and impact of COVID-19 on two of the largest global producers of active pharmaceutical ingredients (APIs) and generics: China and India. APIs is a crucial part of the pharma industry’s strategic plan to combat the COVID-19 pandemic. The majority of APIs for generic drug manufacturing across the globe are sourced from India, which also supplies approximately 30 percent of the generic APIs used in the US. However, Indian manufacturers rely heavily on APIs from China for the production of their medicine formulations, procuring around 70 percent from China, the top global producer and exporter of APIs by volume. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Few Indian major players are as under Alpha Remedies Ltd Ankur Drugs & Pharma Ltd. Cian Healthcare Ltd Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Pan Drugs Ltd Piramal Enterprises Ltd.
Plant capacity: Paracetamol : 1,000.0 Kgs / day Azithromycin : 500.0 Kgs / day Amoxicillin Trihydrate: 500.0 Kgs dayPlant & machinery: 175 lakhs
Working capital: -T.C.I: Cost of Project : Rs 1322 lakhs
Return: 29.00%Break even: 47.00%
Add to Inquiry Add to Inquiry Basket

Manufacturing of Active Pharma Ingredients (API) (Amoxicillin Trihydrate, Azithromycin & Paracetamol).

Production of Active Pharma Ingredients (API) (Amoxicillin Trihydrate, Azithromycin & Paracetamol). Investment Opportunities in Pharmaceutical Industry. An active ingredient (AI) is that the ingredient in an exceedingly pharmaceutical drug that's biologically active. The similar terms active pharmaceutical ingredient (API) and bulk active i.e. bulk medicine are utilized in medicine, and therefore the term active substance could also be used for natural products. Thus, depending on the drug’s administered dosage, the reactions and results differ. Certain drugs are comprised of more than one kind of API. Amoxicillin is an antibiotic used to treat variety of bacterial infections. These include middle ear infection, strep throat, pneumonia, skin infections, and tract infections among others. It’s taken orally, or less usually by injection. Active Pharmaceutical Ingredient (API), is that the term used to check with the biologically active component of a drug product (e.g. tablet, capsule). Drug products are typically composed of many elements. The aforementioned API is that the primary ingredient. Alternative ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components utilized in the drug is known as "formulation." Paracetamol is a commonly used medicine that can help treat pain and reduce a high temperature (fever). It is often recommended as one of the first treatments for pain, as it's safe for most people to take and side effects are rare. Azithromycin is an antibiotic used for the treatment of variety of bacterial infections. This includes middle ear infections, strep throat, pneumonia, traveler's diarrhea, and bound alternative intestinal infections it also can be used for variety of sexually transmitted infections, as well as chlamydia and gonorrhea infections. At the side of alternative medications, it's going to even be used for malaria. It may be taken by mouth or intravenously with doses once per day. It is on the world Health Organization's List of Essential Medicines, the safest and most effective medicines required in a very health system. It’s one in all the most usually prescribed antibiotics in children. Trim ox is on the market as a generic medication. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Azithromycin alone and in combination with different medications is currently being studied for the treatment of coronavirus wellness 2019 (COVID-19). Currently, azithromycin has been used with hydroxychloroquine to treat certain patients with COVID-19. However, there are mixed reports of effectiveness once azithromycin was used at the side of alternative medications to treat other viral respiratory infections. Azithromycin also has been used to treat bacterial infections in hospitalized patients with COVID-19. A lot of information is required before any conclusions may be made regarding the possible advantages and risks of using azithromycin either alone or together with hydroxychloroquine in patients with COVID-19. Amoxicillin Trihydrate may be a hydrate that's the Trihydrate type of amoxicillin; a semisynthetic antibiotic, used either alone or together with potassium clavulanate (under the name Augmentin) for treatment of a variety of bacterial infections. It’s a role as an antibacterial drug and an antimicrobial agent. It contains an amoxicillin. Manufacturing Process The manufacturing process of Paracetamol is summarized in the following steps: -charge acetic acid to the reactor. -add p-nitro phenol as a starting material and iron powder as catalyst. -Heat to temp 80-90 ºC. -The reaction is exothermic and temp will rise to 130 ºC. -After slight cooling -Reflux the reaction at 118ºC for 3-4 hours. -Cool to 60 ºC. -Add methanol to the reaction. -Reflux for 1 hour. -distill the methanol and recycle. -Add water to the obtained cake. -And make a solution -Add activated carbon. -Filter -Dry the cake. -Pulverize the dry cake to get the Paracetamol fine powder. Applications:- Communicable Diseases Oncology Diabetes Cardiovascular Diseases Pain Management Respiratory Diseases Other Therapeutic Applications Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Market Outlook Active Pharmaceutical Ingredient Market is valued at USD 172.69 Billion in 2018 and expected to reach USD 263.80 Billion by 2025 with the CAGR of 6.24% over the forecast period. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates Drugs and over-the-counter (OTC) drugs. In 2019, the prescribed drugs segment is expected to account for the most important share of the APIs market. The demand for drugs falling under this class has increased significantly in recent years because of the rising prevalence of target diseases. Additionally, the most important share of the prescription drugs segment also can be attributed to the increased focus of innovator corporations on the development of specialty drugs and affordability of health care. The implementation of significant federal reforms to improve the affordability of healthcare, especially in the, us has expanded the consumption of each traditional and specialty medicine. Also, inflation has played a key role in enhancing revenue from the sales of prescription drugs, significantly specialty drugs. All these factors are collectively responsible for the large share of this phase. Based on the kind of drug, the APIs market can be classified into two segments prescribed. Manufacturer Insights On the basis of type of manufacturer, the API market has been segmented into merchant and captive APIs. Captive API command the most important share in 2019 because of simple availability of raw materials and intensive capitalization of major key players for the development of high-end manufacturing facilities. API is calculable to be the fastest-growing segment over the forecast period. The segment growth is driven by factors similar to high cost of in-house manufacturing of those molecules and rising demand for biopharmaceuticals. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs Active Pharmaceutical Ingredient (APIs) are portions of any drugs that are biologically active in nature. The APIs have significant use in the manufacturing of effective and safe medicines. Depending on the drug’s administered dosage, the reactions and results take issue according to the requirement and use for specific treatment of diseases. Sure medicine are contained of over one kind of API. medicine are chosen primarily for his or her active ingredients to treat variety of chronic and infectious diseases similar to diabetes, cancer, arthritis, bone & joint infections, pneumonia, otitis, streptococcal pharyngitis, cellulites, and tract infections. However, the standard will vary widely from one whole to a different. Medicine are chosen primarily from active ingredients within the liquid or solid form like tablet or alternative throughout. Global Active Pharmaceutical Ingredient Market Dynamics The key issue for growth of worldwide Active Pharmaceutical Ingredient market is that the rise of demand for the new drug discovery for treatment of various chronic and infectious diseases like HIV, cancer, arthritis, bone & joint infections, hepatitis-B, Aids etc. across the world. According to WHO in 2018, the worldwide cancer burden has up to 18.1 million new cases as well as 9.6 million deaths across the world. Because of such rise within the cases of cancer, the new drugs discovery using the Active Pharmaceutical Ingredient has become essential. Recently in line with the American Chemical Society in 2019, there has been 48 new drugs has been approved by the fad U.S. out of that 11 for new cancer treatments with the innovative molecular pharmaceutical ingredients. However, the Active Pharmaceutical Ingredient market is hampered by would like for prime investment with huge capital demand for research and developments. Moreover rising health cautiousness among the people with technological advancement immense investment for launching of recent drugs and biological products, acquisitions, collaborations, and regional growth can provide huge opportunity for Active Pharmaceutical Ingredient market. For instance in 2019, Raquel has been acquired by Merck & Co. for roughly around USD 2.7 billion in cash, for making cancer drug using Active Pharmaceutical Ingredient with the most recent small-molecule-focused. Expansion of Manufacturing Facilities Creating Lucrative Opportunities for Market Growth Majority of specialty API companies are increasing their manufacturing facilities for specialty active pharmaceutical ingredients (API) to take care of or gain market share. Substantial investments within the growth of approved specialty active pharmaceutical ingredients (API) is one in all the most important factors among key players in the specialty active pharmaceutical ingredients (API) market. For instance, in early 2020, Wuxi STA opened oligonucleotide API manufacturing facility in Changzhou, China to cope up with the increasing demand. In 2018, Cordon Pharma expanded operations with new commercial oligonucleotide active pharmaceutical ingredients (API) manufacturing capabilities at its FDA inspected Colorado facility. The emergence of COVID-19 has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic. Focus on healthcare to drive the active pharmaceutical ingredients market The spending on healthcare has grown at a rapid pace in recent years and it increased at a CAGR of 6.92% between the years 2003 and 2013. The healthcare spending growth was significantly higher than the population growth rate that grew at a CAGR of 1.22% for the same period. The per capita healthcare spending rose from just under US$ 600 in 2003 to above US$ 1000 in 2013, at an average CAGR of 5.62%. The focus on healthcare spending was observed to be a global phenomenon and this directly benefited the active pharmaceutical ingredients market. Related Videos: - Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 billion by 2023 Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit Production of Paracetamol (Acetaminophen), bulk pharmaceutical active ingredient Investment Opportunities in APIs KSMs Drug Intermediates Bulk Drug Industries Manufacturing Business Ideas in Pharmaceutical Industry Key Players Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK). Sun Pharmaceutical Industries Ltd. Tags:- #Activepharmaingredients #pharmaingredients #IndianPharma #medicineingredients #paracetamolingredients #amoxicillinTrihydrate #Azithromycin #COVID19 #Paracetamol #coronavirus #CoronavirusBusiness #COVID2019 #CaronaBUSINESS #lockdownbusiness #businessinlockdown #coronavirusbusiness #Entrepreneurs #covid19business #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #industrialproject #entrepreneurindia #startupbusiness #startupbusinessideas #businessestostart #startupideas #startupbusinesswithnomoney #businessstartupindia #API
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients (API) Amoxicillin Trihydrate, Azithromycin & Paracetamol

Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Active Pharmaceutical Ingredient (API), is the term used to refer to the biologically active component of a drug product (e.g. tablet, capsule). Drug products are usually composed of several components. The aforementioned API is the primary ingredient. Other ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components used in the drug is known as "formulation." India is the seventh largest country in the world and has the second highest population. It has a parliamentary democratic form of government and has abundant natural resources and sufficient oil reserves. The country has a huge skilled, English-speaking, and inexpensive labor force. Its young population and current economic policies have made it one of the largest recipients of FDI in the world. The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. Majority of specialty API companies are increasing their manufacturing facilities for specialty active pharmaceutical ingredients (API) to take care of or gain market share. Substantial investments within the growth of approved specialty active pharmaceutical ingredients (API) is one in all the most important factors among key players in the specialty active pharmaceutical ingredients (API) market. For instance, in early 2020, Wuxi STA opened oligonucleotide API manufacturing facility in Changzhou, China to cope up with the increasing demand. In 2018, Cordon Pharma expanded operations with new commercial oligonucleotide active pharmaceutical ingredients (API) manufacturing capabilities at its FDA inspected Colorado facility. The emergence of COVID-19 has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Few Indian major players are as under Alpha Remedies Ltd Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Dr. Reddy'S Laboratories Ltd. Glaxosmithkline Pharmaceuticals Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd.
Plant capacity: Paracetamol:1,000 Kgs / day Azithromycin:500 Kgs / day Amoxicillin Trihydrate:500 Kgs / dayPlant & machinery: Rs 175 lakhs
Working capital: -T.C.I: Cost of Project : Rs 1322 lakhs
Return: 29.00%Break even: 47.00%
Add to Inquiry Add to Inquiry Basket

Market Research Report on India Active Pharmaceutical Ingredient (API)

Market Research Report on India Active Pharmaceutical Ingredient (API) Market, Growth Rate, Covid-19 Impact, Economic Impact, Size, Share, Trend, Drivers, Competitive Landscape, Opportunity, Limitations, Technological Landscape, Regulatory Framework, PESTEL Analysis, PORTER’s Analysis, Forecast upto 2027 Market by Manufacturing Process (Captive Manufacturing, Contract Manufacturing), By Type of Synthesis (Synthetic, Biotech), By API Formulation (Generic API, Innovative API), By Application (Cardiovascular Disease & Hematopoietic System, Central Nervous System, Anti-infectives, Respiratory, Gastrointestinal Disorders, Urology, and Others and By Region (North India, South India, West India, and East India) The India API Market is expected to Drive Owing to the R&D Activities and Surge in the Incidence of Chronic Disease The India API market projected to reach USD 27.49 billion at a significant CAGR of over 10.23% during the forecasted period of 2020-2027. Due to the rising up gradation of technology across India and the growing incidence of hereditary cardiac disease, it is further projected to accelerate the API market at a significant rate across the country. Furthermore, the propelling focus on precision medicine is precited to accelerate the India active pharmaceutical ingredient market. Moreover, the use of drug development techniques focused on Artificial Intelligence further expected to boost the market. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates Additionally, strategic outsourcing enables enterprises to rely on their core competencies, contributing to improved efficiency, which is anticipated to fuel India's API market. Furthermore, the rising demand for biosimilars across India is predicted to drive the market at a considerable rate. However, the lack of skilled labor is predicted to challenge the growth of the market. Additionally, the increasing penetration of counterfeit drugs further projected to hinder the Indian market's growth substantially. Manufacturing Process Overview in the India API Market Based on the manufacturing process, the India API market segregated into Captive Manufacturing and Contract Manufacturing. The Captive Manufacturing segment is predicted to hold the largest share during the forecasted period of 2020-2027 across the country. It is attributed to the proper manufacturing and strong capitalization of raw materials, which is estimated to boost the India API market significantly. In addition, manufacturing technologies favor in-house production of innovative products to take advantage of the economic opportunities and avoid the proliferation of technologies, which is further predicted to accelerate the market. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Type of Synthesis Overview in the India API Market Based on the type of synthesis, the India API market is segregated into Synthetic and Biotech. The biotech segment is estimated to have the fastest growth rate during the forecasted period of 2020-2027 owing to the propelling technological advancement in the manufacturing process. Additionally, the increasing demand for the therapeutic and diagnostic solution on Red Biotechnology concepts, recombinant, and DNA sequencing technology is anticipated to boost the market. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs API Formulation Overview in the India API Market Based on the API Formulation, the India API market is categorized into Generic API and Innovative API. The Generic API segment is predicted to hold the largest share over the forecasted period of 2020-2027 across the country. It is attributed to the patent expiry of labeled molecules, which is expected to drive the market at a considerable growth rate. In addition, the decreased in the cost of the generic drug is further projected to fuel the India API market. Related Market Research Report: - India Active Pharmaceutical Ingredient (API) Market However, the Innovative API segment is estimated to have a significant growth rate during the forecasted period by 2027 due to the presence of favorable government regulations in the research and development of drugs. Application Overview in the India API Market Based on the Application, the India API market is classified into Anti-infectives, Cardiovascular and Hematopoietic System, Central nervous system, Respiratory, Gastrointestinal Disorders, Urology, and Others. The Cardiovascular and Hematopoietic System segment is expected to hold significant market share in API market over the forecasted period of 2020-2027 across the country due to the increasing prevalence of cardiovascular diseases coupled with the incidence surge of obesity. In addition, the variation in lifestyle has increased the incidence of obesity is further predicted to drive the segment's market. Projects: - Project Reports & Profiles However, the Central nervous system segment is expected to have a considerable growth rate during the forecasted period by 2027 across the country. It is due to the increasing emphasis on early diagnosis & treatment, which is predicted to fuel the market. Additionally, the growing prevalence of neurological diseases and rising funding for neurological diagnostics is estimated to improve the market significantly. Regional Overview in the India API Market By geography, the India API market segmented into North India, South India, West India, and East India. The West India region is projected to hold the largest share during the forecasted period of 2020-2027 owing to technological advancement. In addition, rapidly evolving healthcare facilities and growing healthcare budgets are further anticipated to propel the India API market. Furthermore, the availability of affordable labor across the region is expected to accelerate the region's market. Books: - BOOKS & DATABASES India API Market: Competitive Landscape Companies such as Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Sun Pharmaceutical Industries Limited, GlaxoSmithKline Pharmaceuticals Ltd, Indoco Remedies Ltd., Piramal Enterprises Ltd., Teva Pharmaceutical & Chemical Industries India Pvt. Ltd., Sri Krishna Pharmaceuticals Limited, Pan Drugs Limited, and Other Prominent Players are the key players in the India API market. Tags #MarketResearchReports #MarketReseach #IndustryTrends #IndustryDemands #ActivePharmaceuticalIngredient #API #pharmaceutical #pharmaceuticalindustry #NPCS #projectconsultancy #businessconsultancy #apimarket #chemicalapimarket #biotechapimarket #highpotencyapi #marketforecast #GlobalMarket #GrowthRate #MarketTrend #marketdrivers #marketopportunity #marketanalysis #PESTELAnalysis #MarketEconomic #MarketSize #MarketShare #MarketGrowthRate #markettrends #MarketImpact #marketDemand #MarketStrategy #Marketinvestment #marketinggrowth
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients (API) (Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol)

The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries. But in recent years many corporations have opted to send manufacturing overseas to cut costs. This has caused significant changes to how these drugs are regulated, with more rigorous guidelines and inspections put into place. Cefalexin, is an antibiotic that can treat a number of bacterial infections. It kills gram-positive and some gram-negative bacteria by disrupting the growth of the bacterial cell wall. Cefalexin is a beta-lactam antibiotic within the class of first-generation cephalosporins. It works similarly to other agents within this class, including intravenous cefazolin, but can be taken by mouth. Cefalexin can be used in those who have mild or moderate allergies to penicillin. However, it is not recommended in those with severe penicillin allergies. Ampicillin is an antibiotic used to prevent and treat a number of bacterial infections, such as respiratory tract infections, urinary tract infections, meningitis, salmonellosis, and endocarditis. It may also be used to prevent group B streptococcal infection in newborns. It is used by mouth, by injection into a muscle, or intravenously. Like all antibiotics, it is not useful for the treatment of viral infections. Ampicillin is used to treat infections by many Gram-positive and Gram-negative bacteria. It was the first "broad spectrum" penicillin with activity against Gram-positive bacteria, including Streptococcus pneumoniae, Streptococcus pyogenes, some isolates of Staphylococcus aureus (but not penicillin-resistant or methicillin-resistant strains), Trueperella, and some Enterococcus. Paracetamol (acetaminophen) is a pain reliever and a fever reducer. The exact mechanism of action of is not known. Paracetamol is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers. It relieves pain in mild arthritis but has no effect on the underlying inflammation and swelling of the joint. Paracetamol is generally safe at recommended doses. The recommended maximum daily dose for an adult is three to four grams. Higher doses may lead to toxicity, including liver failure. Serious skin rashes may rarely occur. It appears to be safe during pregnancy and when breastfeeding. In those with liver disease, it may still be used, but in lower doses. It is classified as a mild analgesic. It does not have significant anti-inflammatory activity. How it works is not entirely clear. Ibuprofen is a medication in the nonsteroidal anti-inflammatory drug (NSAID) class that is used for treating pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. It can be used by mouth or intravenously. It typically begins working within an hour India's reliance on pharma ingredient imports has risen over the past few decades due to the higher cost of domestic production, with the price gap reaching as much as 20%-30%, particularly for energy-intensive fermentation-based ingredients used in anti-infectives. Import dependence is more than 90% for some life-saving drugs, including penicillin and ciprofloxacin. India is the seventh largest country in the world and has the second highest population. It has a parliamentary democratic form of government and has abundant natural resources and sufficient oil reserves. The country has a huge skilled, English-speaking, and inexpensive labor force. Its young population and current economic policies have made it one of the largest recipients of FDI in the world. Asia Pacific is expected to be the fastest-growing market over the forecast period. Owing to the availability of affordable labor, major companies in the market are setting up API manufacturing plants in developing countries such as China and India. The global demand of APIs include ageing population, rising expenditures on healthcare, increasing prevalence of lifestyle diseases, etc. Looking forward, the market value is projected to reach US$ 258.8 Billion by 2025, exhibiting a CAGR of 5.6% during 2020-2025. The API market is competitive in nature and is becoming increasingly competitive. Consequently, manufacturers are required to enhance products in order to gain advantage over previously marketed products. The emergence of COVID-19 has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic. The government also notified a scheme to promote bulk drug parks. For selected parks, financial assistance to the tune of 70 per cent of the project cost of common infrastructure facilities will be provided. In the case of Northeast states and hilly states (Himachal Pradesh, Uttarakhand, Union Territory of Jammu & Kashmir, and Union Territory of Ladakh), financial assistance will be 90 per cent of the project cost. The maximum assistance under the scheme for one bulk Drug Park will be limited to Rs 1,000 crore. The total financial outlay of the scheme is Rs 3,000 crore. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Few Indian major players are as under Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Cian Healthcare Ltd Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Indoco Remedies Ltd. Pan Drugs Ltd. Piramal Enterprises Ltd.
Plant capacity: Paracetamol: 500 Kgs / day Cephalexin: 500 Kgs / day Ampicillin Trihydrate: 500 Kgs / day Ibuprofen: 500 Kgs / dayPlant & machinery: Rs 347 lakhs
Working capital: -T.C.I: Cost of Project: Rs 1656 lakhs
Return: 36.00%Break even: 52.00%
Add to Inquiry Add to Inquiry Basket

API Production. Manufacturing of Active Pharma Ingredients (API), Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol.

API Production. Manufacturing of Active Pharma Ingredients (API), Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol. API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine. For example, an active ingredient to relieve pain is included in a painkiller. This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine. Related Projects:- Active Pharma Ingredients (api) The API form that is used in a formulation is often the most thermodynamically stable crystalline form. As such, the phenomenon of hydrogen bonding in combination with there being many functional groups on the API usually results in the available crystalline form being a hydrate. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Ampicillin is used to treat infections by many Gram-positive and Gram-negative bacteria. It was the first "broad spectrum" penicillin with activity against Gram-positive bacteria, including Streptococcus pneumonia, Streptococcus pyogenic, some isolates of Staphylococcus aureus (but not penicillin-resistant or methicillin-resistant strains), Trueperella, and some Enterococcus. Paracetamol is used for the relief of mild to moderate pain. The use of the intravenous form for short-term pain in people in the emergency department is supported by limited evidence. In adults it appears to be useful for migraines, tension headaches, perineal pain after childbirth, and kidney stone pain. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates Ibuprofen is a medication in the nonsteroidal anti-inflammatory drug class that is used for treating pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. Market Outlook The production-linked incentive scheme - which accounts for INR0.9 billion of planned outlay - offers an incentive of up to 20% of sales for fermentation based products and up to 10% for chemical synthesis-based products for the next eight to nine years. This should help to bridge the price gap and make domestic production more competitive. The government has also allocated USD0.4 billion under the capex assistance scheme to fund up to 90% of the investment need to build common infrastructure facilities in three bulk drug parks. We believe this will aid the investment decisions of Indian pharma companies, particularly in the current environment where the focus in on conserving cash. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Active pharmaceutical ingredients are an active ingredient of any drug or tablet, which possesses medicinal properties. Some drugs with combined therapy have many active ingredients to treat different disorders. Related Videos: - Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 billion by 2023 Higher Growth in the APAC Active Pharmaceutical Ingredients Market Healthcare spending has witnessed continued growth for some time now. Even though the proportion of healthcare spending in the APAC region is comparatively low, the growth rate in this strategic region has outpaced that of mature markets in North America and Europe. Rising healthcare spending has led to quality healthcare becoming accessible along with a higher demand for pharmaceutical products across APAC. The pharmaceuticals consumed here are mostly produced in onshore manufacturing units. Furthermore, contract manufacturing organizations are key outsourcing allies for pharmaceutical companies that supply their wares to North America and Europe. Books:- BOOKS & DATABASES Huge investment promises from different countries predict a bright future for India. It has a well-developed administration and an independent judicial system with an ever-growing consumer base. It has a huge pool of hard-working skilled workers in all fields. The government has set up tax and non-tax incentives to establish new industrial entities in specific sectors, which include energy, ports, highways, electronics, and software. Related Videos:- Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit The global active pharmaceutical ingredients market has been broadly segmented based on manufacturer, APIs, drug, therapeutic, and region. In terms of manufacturer, the global market has been classified into in-house API manufacturing and API contract manufacturing. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Related Videos:- Manufacturing Business Ideas in Pharmaceutical Industry Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. Related Projects:- Startup Opportunities in Active Pharma Ingredients The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. Market Research Reports:- India Active Pharmaceutical Ingredient (API) The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Market Research:- Market Research Reports Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Related Projects: - Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Related Projects:- Active Pharma Ingredients (api) (cephalexin, Ampicillin Trihydrate, Ibuprofen And Paracetamol) Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Related Projects: - Active Pharma Ingredients (API) Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Projects: - Project Reports & Profiles For More Details, Click Here: - Key players Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Cian Healthcare Ltd Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Indoco Remedies Ltd. Pan Drugs Ltd. Piramal Enterprises Ltd. Sanofi India Ltd. Sri Krishna Pharmaceuticals Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd. Triton Laboratories Ltd. For More Details, Click Here: - https://bit.ly/32McBPb Tags:- #Activepharmaingredients #pharmaingredients #IndianPharma #medicineingredients #paracetamolingredients #amoxicillinTrihydrate #Azithromycin #COVID19 #Paracetamol #coronavirus #CoronavirusBusiness #COVID2019 #CaronaBUSINESS #lockdownbusiness #businessinlockdown #coronavirusbusiness #Entrepreneurs #covid19business #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #industrialproject #entrepreneurindia #startupbusiness #startupbusinessideas #businessestostart #startupideas #startupbusinesswithnomoney #businessstartupindia #API
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Information
  • One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
  • One Crore is equivalent to ten million (10,000,000)
  • T.C.I is Total Capital Investment
  • We can modify the project capacity and project cost as per your requirement.
  • We can also prepare project report on any subject as per your requirement.
  • Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Page 10 of 31 | Total 306 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 30 31   Next »

About NIIR PROJECT CONSULTANCY SERVICES

Hide »

NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Selection of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.

NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.

^ Top